{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:44:25Z","timestamp":1790171065813,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,28]],"date-time":"2019-12-28T00:00:00Z","timestamp":1577491200000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17K19895"],"award-info":[{"award-number":["17K19895"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K16441"],"award-info":[{"award-number":["19K16441"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["16K15155"],"award-info":[{"award-number":["16K15155"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22136015"],"award-info":[{"award-number":["22136015"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP18ak0101089"],"award-info":[{"award-number":["JP18ak0101089"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Lotte Foundation","award":["Lotte Research Promotion grant"],"award-info":[{"award-number":["Lotte Research Promotion grant"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide, although its pathogenesis remains to be elucidated. A recent study revealed that hepatic Niemann-Pick C1-Like 1 (NPC1L1), a cholesterol re-absorber from bile to the liver expressed on the bile canalicular membrane, is an exacerbation factor of NAFLD. Indeed, transgenic mice with hepatic expression of human NPC1L1 under a liver-specific promoter (L1-Tg mice) developed steatosis with a high-fat diet (HFD) containing cholesterol within a few weeks. However, the mechanism underlying diet-induced hepatic NPC1L1-mediated lipid accumulation is poorly defined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>To achieve a deeper understanding of steatosis development in L1-Tg mice, the biochemical features of hepatic NPC1L1-mediated steatosis were investigated. Hemizygous L1-Tg mice and wild-type littermate controls fed a HFD or control-fat diet were used. At the indicated time points, the livers were evaluated for cholesterol and triglyceride (TG) contents as well as mRNA levels of hepatic genes involved in the maintenance of lipid homeostasis. The hepatic ability to secrete very low-density lipoprotein (VLDL)-TG was also investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Unlike the livers of wild-type mice that have little expression of hepatic Npc1l1, the livers of L1-Tg mice displayed time-dependent changes that indicated steatosis formation. In steatosis, there were three different stages of development: mild accumulation of hepatic cholesterol and TG (early stage), acceleration of hepatic TG accumulation (middle stage), and further accumulation of hepatic cholesterol (late stage). In the early stage, between WT and L1-Tg mice fed a HFD for 2\u2009weeks, there were no significant differences in the hepatic expression of Ppar\u03b1, Acox1, Fat\/Cd36, Srebf1, and Srebf2; however, the hepatic ability to secrete VLDL-TG decreased in L1-Tg mice (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Furthermore, this decrease was completely prevented by administration of ezetimibe, an NPC1L1-selective inhibitor.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Hepatic NPC1L1 exacerbates diet-induced steatosis, which was accompanied by decreased hepatic ability of VLDL-TG secretion. The obtained results provide a deeper understanding of L1-Tg mice as a promising NAFLD animal model that is able to re-absorb biliary-secreted cholesterol similar to humans. Furthermore, this work supports further studies of the pathophysiological impact of re-absorbed biliary cholesterol on the regulation of hepatic lipid homeostasis.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12944-019-1179-0","type":"journal-article","created":{"date-parts":[[2019,12,28]],"date-time":"2019-12-28T11:02:45Z","timestamp":1577530965000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pathophysiological importance of bile cholesterol reabsorption: hepatic NPC1L1-exacerbated steatosis and decreasing VLDL-TG secretion in mice fed a high-fat diet"],"prefix":"10.1186","volume":"18","author":[{"given":"Yu","family":"Toyoda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tappei","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihide","family":"Yamanashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,28]]},"reference":[{"key":"1179_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41575-019-0144-8","volume":"16","author":"AJ Sanyal","year":"2019","unstructured":"Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2019;16:377\u201386.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1179_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology."},{"key":"1179_CR3","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908\u201322.","journal-title":"Nat Med"},{"key":"1179_CR4","doi-asserted-by":"publisher","first-page":"2548154","DOI":"10.1155\/2018\/2548154","volume":"2018","author":"O Tirosh","year":"2018","unstructured":"Tirosh O. Hypoxic signaling and cholesterol lipotoxicity in fatty liver disease progression. Oxidative Med Cell Longev. 2018;2018:2548154.","journal-title":"Oxidative Med Cell Longev"},{"key":"1179_CR5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.plipres.2012.11.002","volume":"52","author":"G Musso","year":"2013","unstructured":"Musso G, Gambino R, Cassader M. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog Lipid Res. 2013;52:175\u201391.","journal-title":"Prog Lipid Res"},{"key":"1179_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrgastro.2010.191","volume":"8","author":"L Hebbard","year":"2011","unstructured":"Hebbard L, George J. Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2011;8:35\u201344.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1179_CR7","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1172\/JCI30060","volume":"117","author":"RE Temel","year":"2007","unstructured":"Temel RE, Tang W, Ma Y, Rudel LL, Willingham MC, Ioannou YA, Davies JP, Nilsson LM, Yu L. Hepatic Niemann-pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest. 2007;117:1968\u201378.","journal-title":"J Clin Invest"},{"key":"1179_CR8","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1126\/science.1093131","volume":"303","author":"SW Altmann","year":"2004","unstructured":"Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, et al. Niemann-pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303:1201\u20134.","journal-title":"Science."},{"key":"1179_CR9","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/hep.24772","volume":"55","author":"Y Yamanashi","year":"2012","unstructured":"Yamanashi Y, Takada T, Shoda J, Suzuki H. Novel function of Niemann-pick C1-like 1 as a negative regulator of Niemann-pick C2 protein. Hepatology. 2012;55:953\u201364.","journal-title":"Hepatology."},{"key":"1179_CR10","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.bbalip.2011.05.013","volume":"1811","author":"W Tang","year":"2011","unstructured":"Tang W, Jia L, Ma Y, Xie P, Haywood J, Dawson PA, Li J, Yu L. Ezetimibe restores biliary cholesterol excretion in mice expressing Niemann-pick C1-like 1 only in liver. Biochim Biophys Acta. 2011;1811:549\u201355.","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"1179_CR11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1096\/fba.2018-00044","volume":"1","author":"Yu Toyoda","year":"2019","unstructured":"Toyoda Y, Takada T, Umezawa M, Tomura F, Yamanashi Y, Takeda K, Suzuki H. Identification of hepatic NPC1L1 as an NAFLD risk factor evidenced by ezetimibe-mediated steatosis prevention and recovery. FASEB Bioadv. 2019;1:283\u201395.","journal-title":"FASEB BioAdvances"},{"key":"1179_CR12","doi-asserted-by":"publisher","first-page":"24586","DOI":"10.1038\/srep24586","volume":"6","author":"Y Toyoda","year":"2016","unstructured":"Toyoda Y, Takada T, Suzuki H. Halogenated hydrocarbon solvent-related cholangiocarcinoma risk: biliary excretion of glutathione conjugates of 1,2-dichloropropane evidenced by untargeted metabolomics analysis. Sci Rep. 2016;6:24586.","journal-title":"Sci Rep"},{"key":"1179_CR13","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0022-2275(20)37649-5","volume":"37","author":"X Li","year":"1996","unstructured":"Li X, Catalina F, Grundy SM, Patel S. Method to measure apolipoprotein B-48 and B-100 secretion rates in an individual mouse: evidence for a very rapid turnover of VLDL and preferential removal of B-48- relative to B-100-containing lipoproteins. J Lipid Res. 1996;37:210\u201320.","journal-title":"J Lipid Res"},{"key":"1179_CR14","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41598-017-00685-9","volume":"7","author":"H Yamamoto","year":"2017","unstructured":"Yamamoto H, Takada T, Yamanashi Y, Ogura M, Masuo Y, Harada-Shiba M, Suzuki H. VLDL\/LDL acts as a drug carrier and regulates the transport and metabolism of drugs in the body. Sci Rep. 2017;7:633.","journal-title":"Sci Rep"},{"key":"1179_CR15","doi-asserted-by":"publisher","first-page":"16237","DOI":"10.1073\/pnas.252582399","volume":"99","author":"L Yu","year":"2002","unstructured":"Yu L, Hammer RE, Li-Hawkins J, Von Bergmann K, Lutjohann D, Cohen JC, Hobbs HH. Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc Natl Acad Sci U S A. 2002;99:16237\u201342.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1179_CR16","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1073\/pnas.98.4.2011","volume":"98","author":"R Wang","year":"2001","unstructured":"Wang R, Salem M, Yousef IM, Tuchweber B, Lam P, Childs SJ, Helgason CD, Ackerley C, Phillips MJ, Ling V. Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahepatic cholestasis. Proc Natl Acad Sci U S A. 2001;98:2011\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1179_CR17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/0092-8674(93)90380-9","volume":"75","author":"JJ Smit","year":"1993","unstructured":"Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter L, Mol CA, Ottenhoff R, van der Lugt NM, van Roon MA, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell. 1993;75:451\u201362.","journal-title":"Cell."},{"key":"1179_CR18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2217\/clp.14.65","volume":"10","author":"A Asimakopoulou","year":"2015","unstructured":"Asimakopoulou A, Weiskirchen R. Lipocalin 2 in the pathogenesis of fatty liver disease and nonalcoholic steatohepatitis. Clin Lipidol. 2015;10:47\u201367.","journal-title":"Clin Lipidol"},{"key":"1179_CR19","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.tips.2015.07.001","volume":"36","author":"GD Norata","year":"2015","unstructured":"Norata GD, Tsimikas S, Pirillo A, Catapano AL. Apolipoprotein C-III: from pathophysiology to pharmacology. Trends Pharmacol Sci. 2015;36:675\u201387.","journal-title":"Trends Pharmacol Sci"},{"key":"1179_CR20","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.cmet.2012.03.007","volume":"15","author":"S Fu","year":"2012","unstructured":"Fu S, Watkins SM, Hotamisligil GS. The role of endoplasmic reticulum in hepatic lipid homeostasis and stress signaling. Cell Metab. 2012;15:623\u201334.","journal-title":"Cell Metab"},{"key":"1179_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.cmet.2006.07.006","volume":"4","author":"M Mari","year":"2006","unstructured":"Mari M, Caballero F, Colell A, Morales A, Caballeria J, Fernandez A, Enrich C, Fernandez-Checa JC, Garcia-Ruiz C. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab. 2006;4:185\u201398.","journal-title":"Cell Metab"},{"key":"1179_CR22","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1038\/ncomms4878","volume":"5","author":"L Jia","year":"2014","unstructured":"Jia L, Vianna CR, Fukuda M, Berglund ED, Liu C, Tao C, Sun K, Liu T, Harper MJ, Lee CE, et al. Hepatocyte toll-like receptor 4 regulates obesity-induced inflammation and insulin resistance. Nat Commun. 2014;5:3878.","journal-title":"Nat Commun"},{"key":"1179_CR23","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1002\/hep.24552","volume":"54","author":"L Li","year":"2011","unstructured":"Li L, Chen L, Hu L, Liu Y, Sun HY, Tang J, Hou YJ, Chang YX, Tu QQ, Feng GS, et al. Nuclear factor high-mobility group box1 mediating the activation of toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology. 2011;54:1620\u201330.","journal-title":"Hepatology."},{"key":"1179_CR24","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1194\/jlr.M026575","volume":"53","author":"M Kurano","year":"2012","unstructured":"Kurano M, Hara M, Tsuneyama K, Okamoto K, Iso ON, Matsushima T, Koike K, Tsukamoto K. Modulation of lipid metabolism with the overexpression of NPC1L1 in mouse liver. J Lipid Res. 2012;53:2275\u201385.","journal-title":"J Lipid Res"},{"key":"1179_CR25","doi-asserted-by":"publisher","first-page":"275ra23","DOI":"10.1126\/scitranslmed.3010329","volume":"7","author":"T Takada","year":"2015","unstructured":"Takada T, Yamanashi Y, Konishi K, Yamamoto T, Toyoda Y, Masuo Y, Yamamoto H, Suzuki H. NPC1L1 is a key regulator of intestinal vitamin K absorption and a modulator of warfarin therapy. Sci Transl Med. 2015;7:275ra23.","journal-title":"Sci Transl Med"},{"key":"1179_CR26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1124\/mol.107.043034","volume":"74","author":"K Narushima","year":"2008","unstructured":"Narushima K, Takada T, Yamanashi Y, Suzuki H. Niemann-pick C1-like 1 mediates alpha-tocopherol transport. Mol Pharmacol. 2008;74:42\u20139.","journal-title":"Mol Pharmacol"},{"key":"1179_CR27","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1124\/jpet.106.114181","volume":"320","author":"Y Yamanashi","year":"2007","unstructured":"Yamanashi Y, Takada T, Suzuki H. Niemann-pick C1-like 1 overexpression facilitates ezetimibe-sensitive cholesterol and beta-sitosterol uptake in CaCo-2 cells. J Pharmacol Exp Ther. 2007;320:559\u201364.","journal-title":"J Pharmacol Exp Ther"},{"key":"1179_CR28","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/nm.2581","volume":"18","author":"B Sainz Jr","year":"2012","unstructured":"Sainz B Jr, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA, et al. Identification of the Niemann-pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med. 2012;18:281\u20135.","journal-title":"Nat Med"},{"key":"1179_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/nm.3417","volume":"20","author":"PS Li","year":"2014","unstructured":"Li PS, Fu ZY, Zhang YY, Zhang JH, Xu CQ, Ma YT, Li BL, Song BL. The clathrin adaptor numb regulates intestinal cholesterol absorption through dynamic interaction with NPC1L1. Nat Med. 2014;20:80\u20136.","journal-title":"Nat Med"},{"key":"1179_CR30","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.cmet.2008.04.001","volume":"7","author":"L Ge","year":"2008","unstructured":"Ge L, Wang J, Qi W, Miao HH, Cao J, Qu YX, Li BL, Song BL. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab. 2008;7:508\u201319.","journal-title":"Cell Metab"},{"key":"1179_CR31","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1124\/dmd.107.015628","volume":"35","author":"T Yamamoto","year":"2007","unstructured":"Yamamoto T, Ito K, Honma M, Takada T, Suzuki H. Cholesterol-lowering effect of ezetimibe in uridine diphosphate glucuronosyltransferase 1A-deficient (Gunn) rats. Drug Metab Dispos. 2007;35:1455\u20138.","journal-title":"Drug Metab Dispos"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-019-1179-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12944-019-1179-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-019-1179-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T10:45:04Z","timestamp":1613299504000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-019-1179-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1179"],"URL":"https:\/\/doi.org\/10.1186\/s12944-019-1179-0","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"13 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animals received humane care according to criteria outlined in the Guide for the Care and Use of Laboratory Animals prepared by the National Academy of Sciences and published by the National Institutes of Health. All animal experiments in this study were performed according to methods approved by the Institutional Animal Care and Use Committee of the University of Tokyo.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"234"}}